Edwards Lifesciences designs and manufactures implanted devices to treat advanced cardiovascular diseases. It offers transcatheter-delivered devices to treat aortic stenosis, which is a blockage of the aortic valve due to calcification. These devices are marketed under the Edwards SAPIEN family of valves system. Edwards was founded in 1958 and is based in Irvine, California. It has roughly 16,000 employees. The EW shares are a component of the S&P 500.

Stocks were in the red for much of the day on Thursday, with but reversed course and closed higher on hopes for an end to the war in Iran. The Dow Jones Industrial Average was up 0.55%, the S&P 500 0.17%, and the Nasdaq Composite 0.09%.

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Edwards Lifesciences provides products and technologies to treat advanced cardiovascular diseases in the U.S., Europe, Japan, and globally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the Pascal, Evoque, Precision, and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name. Edwards was founded in 1958 and is based in Irvine, California. It has roughly 16,000 employees. The EW shares are a component of the S&P 500.